MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

Boston Scientific Corp.

Abrir

SetorSaúde

97.45 0.84

Visão Geral

Variação de preço das ações

24h

Atual

Mín

95.92

Máximo

98.45

Indicadores-chave

By Trading Economics

Rendimento

123M

795M

Vendas

398M

5.1B

P/E

Médio do Setor

58.458

35.739

Margem de lucro

15.708

Funcionários

53,000

EBITDA

155M

1.4B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+31.79% upside

Dividendos

By Dow Jones

Próximos Ganhos

22 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-8.1B

145B

Abertura anterior

96.61

Fecho anterior

97.45

Sentimento de Notícias

By Acuity

44%

56%

130 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Boston Scientific Corp. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de jul. de 2025, 11:16 UTC

Ganhos

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

23 de abr. de 2025, 12:16 UTC

Ganhos
Grandes Movimentos do Mercado

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

3 de mar. de 2025, 12:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

9 de set. de 2025, 12:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific to Buy Elutia's Bioenvelope Business for $88M

9 de set. de 2025, 12:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88M

23 de jul. de 2025, 10:32 UTC

Ganhos

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

23 de jul. de 2025, 10:31 UTC

Ganhos

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific 2Q EPS 53c >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific 2Q Sales $5.06B >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific 2Q Adj EPS 75c >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

23 de jul. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees 3Q EPS 44c-EPS 46c >BSX

23 de abr. de 2025, 10:32 UTC

Ganhos

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

23 de abr. de 2025, 10:31 UTC

Ganhos

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific 1Q EPS 45c >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific 1Q Adj EPS 75c >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific 1Q Sales $4.66B >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

3 de mar. de 2025, 11:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3 de mar. de 2025, 11:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3 de mar. de 2025, 11:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5 de fev. de 2025, 21:33 UTC

Ganhos

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 de fev. de 2025, 15:20 UTC

Ganhos

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

Comparação entre Pares

Variação de preço

Boston Scientific Corp. Previsão

Preço-alvo

By TipRanks

31.79% parte superior

Previsão para 12 meses

Média 126.32 USD  31.79%

Máximo 140 USD

Mínimo 115 USD

Com base em 23 analistas de Wall Street que oferecem metas de preço de 12 meses para Boston Scientific Corp. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

23 ratings

23

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

102.95 / 104.93Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

130 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat